CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

about

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

Item

http://www.wikidata.org/entity/Q57821084

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@en

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@nl

type

Item

label

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@en

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@nl

prefLabel

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@en

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@nl

P1476

CDK4/6 inhibitors in hormone r ...... er: Are we at the finish line?

@en

P2093

Clinton Yam

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

Mien-Chie Hung

http://www.w3.org/2001/XMLSchema#string

P2860

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

Palbociclib and Letrozole in Advanced Breast Cancer.

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

P304

34193-34195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.18632/ONCOTARGET.26134

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30344934

http://www.w3.org/2001/XMLSchema#string

P932

6188130

http://www.w3.org/2001/XMLSchema#string